search
Back to results

Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study

Primary Purpose

Diabetes Type 2, Pre-diabetes

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Intermittent Fasting
Sponsored by
gino gaddini
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Type 2

Eligibility Criteria

18 Years - 69 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

**Subjects must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study**

Inclusion Criteria:

  • Male and female Active Duty members and DoD beneficiaries ages 18-69
  • Diagnosed with Type 2 Diabetes or pre-diabetic
  • Prescribed/taking Metformin 500mg to 2000mg daily

Exclusion Criteria:

  • History of recurrent hypoglycemic events on present medication regimen
  • Drugs/medication with known increase in hypoglycemic events [Include basal insulin, rapid acting insulin, sulfonylureas, etc.). Metformin is not known to cause hypoglycemia.
  • Pregnant
  • Medication-induced or secondary diabetes
  • Known abnormal hematocrit

Sites / Locations

  • Mike O'Callaghan Military Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intermittent Fasting

Arm Description

Modified 5:2 intermittent fasting

Outcomes

Primary Outcome Measures

Number of hypoglycemic events
This study's intent is to investigate the safety of this intervention for use in a broader scope. It is imperative that risks are known for each subpopulation of diabetics. To this point, our literature review indicates that hypoglycemic events did occur at higher rates in fasting populations taking hypoglycemic medications. We intend to look at rates of hypoglycemia on those not on hypoglycemic medications to assess if this trend continues.

Secondary Outcome Measures

Full Information

First Posted
May 1, 2019
Last Updated
June 1, 2021
Sponsor
gino gaddini
search

1. Study Identification

Unique Protocol Identification Number
NCT03938441
Brief Title
Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study
Official Title
Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Terminated
Why Stopped
Slow enrollment and PI Graduating Residency in June 2021.
Study Start Date
July 31, 2019 (Actual)
Primary Completion Date
May 28, 2021 (Actual)
Study Completion Date
May 28, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
gino gaddini

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to establish safety of biweekly intermittent fasting in the setting of type 2 diabetes mellitus or prediabetes under treatment with non-hypoglycemic agents (e.g. metformin).
Detailed Description
This study is proposed as a prospective interventional cohort safety study for biweekly intermittent fasting. In the effort to improve compliance of lifetime dietary change, the version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies. On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories. Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Type 2, Pre-diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intermittent Fasting
Arm Type
Experimental
Arm Description
Modified 5:2 intermittent fasting
Intervention Type
Other
Intervention Name(s)
Intermittent Fasting
Intervention Description
The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies. On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories. Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day.
Primary Outcome Measure Information:
Title
Number of hypoglycemic events
Description
This study's intent is to investigate the safety of this intervention for use in a broader scope. It is imperative that risks are known for each subpopulation of diabetics. To this point, our literature review indicates that hypoglycemic events did occur at higher rates in fasting populations taking hypoglycemic medications. We intend to look at rates of hypoglycemia on those not on hypoglycemic medications to assess if this trend continues.
Time Frame
Number will vary depending on the number of hypoglycaemic events per each subject and will be recorded throughout study until completion at 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
**Subjects must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study** Inclusion Criteria: Male and female Active Duty members and DoD beneficiaries ages 18-69 Diagnosed with Type 2 Diabetes or pre-diabetic Prescribed/taking Metformin 500mg to 2000mg daily Exclusion Criteria: History of recurrent hypoglycemic events on present medication regimen Drugs/medication with known increase in hypoglycemic events [Include basal insulin, rapid acting insulin, sulfonylureas, etc.). Metformin is not known to cause hypoglycemia. Pregnant Medication-induced or secondary diabetes Known abnormal hematocrit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul F Crawford, MD
Organizational Affiliation
US Air Force
Official's Role
Study Director
Facility Information:
Facility Name
Mike O'Callaghan Military Medical Center
City
Nellis Air Force Base
State/Province
Nevada
ZIP/Postal Code
89191
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
We do not plan on sharing data
Citations:
PubMed Identifier
27833048
Citation
Carter S, Clifton PM, Keogh JB. The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes; a pragmatic pilot trial. Diabetes Res Clin Pract. 2016 Dec;122:106-112. doi: 10.1016/j.diabres.2016.10.010. Epub 2016 Oct 19.
Results Reference
background
PubMed Identifier
28465792
Citation
Arnason TG, Bowen MW, Mansell KD. Effects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study. World J Diabetes. 2017 Apr 15;8(4):154-164. doi: 10.4239/wjd.v8.i4.154.
Results Reference
background
PubMed Identifier
23582559
Citation
Azevedo FR, Ikeoka D, Caramelli B. Effects of intermittent fasting on metabolism in men. Rev Assoc Med Bras (1992). 2013 Mar-Apr;59(2):167-73. doi: 10.1016/j.ramb.2012.09.003.
Results Reference
background
PubMed Identifier
12821964
Citation
Ash S, Reeves MM, Yeo S, Morrison G, Carey D, Capra S. Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with Type II diabetes: a randomised trial. Int J Obes Relat Metab Disord. 2003 Jul;27(7):797-802. doi: 10.1038/sj.ijo.0802295.
Results Reference
background
PubMed Identifier
26135345
Citation
Horne BD, Muhlestein JB, Anderson JL. Health effects of intermittent fasting: hormesis or harm? A systematic review. Am J Clin Nutr. 2015 Aug;102(2):464-70. doi: 10.3945/ajcn.115.109553. Epub 2015 Jul 1.
Results Reference
background
PubMed Identifier
29405359
Citation
Corley BT, Carroll RW, Hall RM, Weatherall M, Parry-Strong A, Krebs JD. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med. 2018 May;35(5):588-594. doi: 10.1111/dme.13595. Epub 2018 Feb 27.
Results Reference
background
PubMed Identifier
12502617
Citation
Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, Nathan D, Vinicor F; American Diabetes Association. Implications of the United kingdom prospective diabetes study. Diabetes Care. 2003 Jan;26 Suppl 1:S28-32. doi: 10.2337/diacare.26.2007.s28. No abstract available.
Results Reference
background
Citation
Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2015.
Results Reference
background

Learn more about this trial

Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study

We'll reach out to this number within 24 hrs